Metabolic and Lipoprotein Changes in Type 2 Diabetes Patients Treated with Empagliflozin. (PubMed, Biomedicines) - Sep 27, 2026 - " Empagliflozin positively affected serum magnesium, iron metabolism, and inflammatory markers without altering lipoprotein profiles. Further research is needed to elucidate SGLT2i's molecular mechanisms underlying their pleiotropic-cardioprotective effects."
Journal • Diabetes • Inflammation • Metabolic Disorders • Type 2 Diabetes Mellitus • IL6
|
|
Anastasia Parthymou; Dionysios V Chartoumpekis; Evagelia E Habeos; George I Habeos; Georgios K Markantes; Konstantinos Dimitropoulos; Marios Papasotiriou; Markos Marangos
|